Evestia Clinical has acquired Berlin-based CRO and scientific consultancy ICRC-Weyer GmbH to expand its European presence and enhance its full-service clinical research capabilities. The acquisition adds specialist expertise in biostatistics, data management and medical writing to Evestia Clinical’s portfolio and strengthens operational delivery across Germany and the wider European market.

ICRC-Weyer, founded in 1993, has a long-standing history in data-driven clinical research and provides consulting across the full development cycle. Its capabilities include biostatistics, data management, medical review, medical writing and pharmacovigilance, supporting studies from Phase I-IV and medical device trials, including complex early-phase studies and adaptive designs.

The integration of ICRC-Weyer allows Evestia Clinical to offer biotech innovators more comprehensive, end-to-end support for clinical programs, spanning core therapeutic areas including oncology, neurology and rare diseases. At the same time, ICRC-Weyer’s clients gain access to Evestia Clinical’s global service offering, including project and site management, regulatory services, clinical monitoring, quality assurance and functional service provider solutions.

Richard Barfield, chairman of Evestia Clinical, said: “As we mark one year since the launch of Evestia Clinical, this acquisition is another significant step in our strategy to build a truly global, independent specialist CRO with the capabilities to support biotech innovators worldwide. Our expanded specialist capabilities strengthen Evestia Clinical’s position as a trusted, full-service partner for biotech innovators advancing complex therapies in oncology, neurology, and rare diseases.”

Lewis Cameron, chief executive officer of Evestia Clinical, added: “The acquisition of ICRC-Weyer is a targeted investment that strengthens Evestia Clinical’s operational delivery in Europe. Integrating ICRC-Weyer’s capabilities into our existing offering enhances the depth of support we provide to biotech innovators and enables more seamless, end-to-end clinical research solutions in complex, high-research therapeutic areas. With a strong presence in the United States through our integration with ARG, and now an established base in Europe with on-the-ground expertise in Germany complementing operations already established in Spain, Italy, and France, we are broadening our global footprint.”

Johann Daniel Weyer, managing director of ICRC-Weyer, said: “Joining Evestia Clinical is a natural step in ICRC-Weyer’s development. By combining ICRC-Weyer’s expertise in scientific consultancy and back-office CRO services with Evestia Clinical’s global reach and specialist therapeutic focus, we will offer clients a stronger and more comprehensive proposition as they navigate increasingly complex clinical development programs across Europe and beyond.”

ICRC-Weyer will continue to operate under its own brand, and all employees will transition to Evestia Clinical. Johann Daniel Weyer will join the Evestia Clinical leadership team, and there will be no changes to services or teams. Terms of the deal have not been disclosed.

The acquisition follows the launch of Evestia Clinical last year and reflects the company’s strategy to provide global, full-service support to biotech innovators. Evestia Clinical, backed by Kester Capital, offers a full suite of clinical development services, including regulatory support, clinical monitoring, medical writing, data management, pharmacovigilance, quality assurance, and functional service provider solutions.